Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Hyperprogressive disease (HPD)"'
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTImmune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic option for large cell neuroendocrine carcinoma (LCNEC). However, various studies have suggested a potential risk of hyperprogressive disease (HPD) in patients receivi
Externí odkaz:
https://doaj.org/article/4bdbddadbc0142e580911cf85e32913c
Autor:
Jiajie He, Rui Zou, Liqing Kang, Lingzi Yu, Peng Wang, Yang Shao, Junheng Liang, Depei Wu, Zhengming Jin, Changju Qu
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Chimeric antigen receptor T-cell therapy (CAR-T) has been widely applied in the clinical practice of relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) due to its promising effects. Hyperprogressive disease (HPD) has gained attention for
Externí odkaz:
https://doaj.org/article/24ddf2eff3fa4b34b2c9f71339a0eea4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tomoyo Oguri, Shinji Sasada, Sachiko Seki, Saori Murata, Yumi Tsuchiya, Kota Ishioka, Saeko Takahashi, Reishi Seki, Shigemichi Hirose, Ryohei Katayama, Morio Nakamura
Publikováno v:
Respiratory Medicine Case Reports, Vol 33, Iss , Pp 101405- (2021)
A 66-year old man with non-smoking history was diagnosed with pulmonary pleomorphic carcinoma of the right lower lobe. The carcinoma metastasized to the brain, lungs, pleura, and mediastinal lymph nodes. It was positive for epidermal growth factor re
Externí odkaz:
https://doaj.org/article/4fcb4237827742ea9d02803136ffb95a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Translational Lung Cancer Research. 10(7):3276-3291
Objective: Update the last known review, and summarize the definitions, diagnostic criteria, reported risk factors, possible mechanisms and potential biomarkers of hyperprogressive disease ( HPD) under immunotherapy.Background: Immunotherapy is a rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od________83::76915d311d8f1c0914fa96eb7947956d
https://doi.org/10.21037/tlcr-21-575
https://doi.org/10.21037/tlcr-21-575
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Zehra Ordulu, Andrew George, Kelsey E. Huntington, Ilyas Sahin, Lanlan Zhou, Wafik S. El-Deiry, Shengliang Zhang
Publikováno v:
Oncotarget
Immunotherapy is an established treatment modality in oncology. However, in addition to primary or acquired therapy resistance with immune checkpoint blockade (ICB), hyperprogressive disease (HPD) or hyperprogression (HP) with acceleration of tumor g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebc90cd4f979d17ed13395ae7ac24f51
https://pubmed.ncbi.nlm.nih.gov/34676046
https://pubmed.ncbi.nlm.nih.gov/34676046
Autor:
Yumi Tsuchiya, Morio Nakamura, Ryohei Katayama, Shinji Sasada, Saori Murata, Tomoyo Oguri, Saeko Takahashi, Reishi Seki, Kota Ishioka, Shigemichi Hirose, Sachiko Seki
Publikováno v:
Respiratory Medicine Case Reports, Vol 33, Iss, Pp 101405-(2021)
Respiratory Medicine Case Reports
Respiratory Medicine Case Reports
A 66-year old man with non-smoking history was diagnosed with pulmonary pleomorphic carcinoma of the right lower lobe. The carcinoma metastasized to the brain, lungs, pleura, and mediastinal lymph nodes. It was positive for epidermal growth factor re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38627949a97470069f201ecc49372226
http://www.sciencedirect.com/science/article/pii/S2213007121000678
http://www.sciencedirect.com/science/article/pii/S2213007121000678
Autor:
Claudia Proto, Marina Chiara Garassino, Diego Signorelli, Giuseppe Lo Russo, Roberto Ferrara, A. Prelaj
Publikováno v:
Transl Lung Cancer Res
In the immunotherapy era, considering the prolonged survival benefit and responses observed with immunecheckpoint inhibitors (ICI) in many cancer types, the identification of patients with rapid progression (PD) and deaths upon ICI has found some ske
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feb9dee967586746eac263e3f2f32790
http://hdl.handle.net/11311/1220886
http://hdl.handle.net/11311/1220886
